SCHEMBL10102352

SCHEMBL10102352

C#CC(O)(c1ccc(C)cc1)c1ccc2c(c1)OCO2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
SMN1; SMN2 Q16637 6/20 0.45
MAPT P10636 6/20 0.45
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
ALOX12 P18054 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 2/20 0.40
USP2 O75604 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40
CASP7 P55210 1/20 0.40
HBB P68871 1/20 0.40
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7816281 0.87 KIF11 (0.44) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL10106909 0.85 ALDH1A1 (0.45) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL10102347 0.83 NPC1 (0.47) NPC1RAB9AMAPTALDH1A1KMT2A
SCHEMBL8782519 0.79 TSHR (0.44) NPC1RAB9AMAPTTDP1ALDH1A1
SCHEMBL10102335 0.76 CYP19A1 (0.38) NPC1RAB9ASMN1; SMN2MAPTTDP1
SCHEMBL933157 0.72 CYP3A4 (0.50) NPC1RAB9ASMN1; SMN2MAPTTDP1
SCHEMBL4796677 0.72 MEN1 (0.44) SMN1; SMN2ALDH1A1LMNAMEN1ALOX12
SCHEMBL10102337 0.70 CYP19A1 (0.44) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL10102361 0.70 ACHE (0.47) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL25954129 0.69 TEAD4 (0.44) NPC1RAB9ASMN1; SMN2MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 NPC1 1130/4885RAB9A 1112/4885SMN1; SMN2 1096/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 NPC1 809/4885RAB9A 841/4885SMN1; SMN2 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.